|
시장보고서
상품코드
1907938
AAV 유전자 치료 시장 : 벡터 혈청형별, 치료 영역별, 표적 조직별, 적응증유형별, 유전자 탑재 기준별, 개발 단계별, 제조 유형별, 최종 사용자별, 지역별AAV Gene Therapy Market, By Vector Serotype, By Therapeutic Area, By Target Tissue, By Indication Type, By Gene Payload Type, By Development Stage, By Manufacturing Type, By End User, By Geography |
||||||
AAV 유전자 치료 시장은 2025년에 34억 6,000만 달러로 평가되었고, 2032년까지 169억 7,000만 달러에 이를 것으로 예측됩니다. 2025년부터 2032년까지 연평균 복합 성장률(CAGR) 25.5%로 성장할 전망입니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2024년 | 시장 규모(2025년) | 34억 6,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2025-2032년 |
| 예측기간 CAGR(2025-2032년) | 25.50% | 예측 금액(2032년) | 169억 7,000만 달러 |
세계의 AAV 유전자 치료 시장은 현대 의학의 혁신적인 분야로, 아데노 관련 바이러스(AAV) 벡터를 고도의 전달 시스템으로 활용하고 치료 유전자를 표적 세포로 직접 수송함으로써 다양한 유전성 질환과 후천성 질환의 치료를 실현하고 있습니다.
AAV 유전자 치료는 탁월한 안전성 프로파일, 최소한의 면역원성 및 숙주 유전체에 통합되지 않고 지속적인 유전자 발현을 달성할 수 있는 능력을 통해 획기적인 치료 접근법으로 등장했습니다.
이 혁신적인 치료법은 AAV 벡터의 독특한 특성을 활용합니다. AAV 벡터는 자연적으로 존재하는 비병원성 바이러스로, 복제 능력을 제거하면서 여러 조직 유형에 걸친 분열 세포와 비분열 세포 모두에 유전자를 도입하는 뛰어난 능력을 유지하도록 광범위한 유전자 조작이 실시되고 있습니다.
시장은 유전성 망막 질환, 혈우병, 척수성 근위축증, 다양한 중추신경계 질환 등 다양한 치료 응용 분야를 포괄하고 있으며, 수많은 임상시험에서 유망한 효능을 보이고 있습니다. 세계 규제 당국이 AAV 기반 유전자 치료를 계속 승인하고 제약회사가 R&D 노력을 강화하는 가운데 벡터 공학 기술 진보, 제조 공정 개선, 치료 대상 확대가 함께 AAV 유전자 치료는 지금까지 치료 불가능한 유전성 질환에 대한 변혁적인 해결책으로 자리매김해 시장은 전례 없는 성장을 이루고 있습니다.
시장 역학
세계의 AAV 유전자 치료 시장은 건강 관리 분야 전반에 걸쳐 강력한 확장을 촉진하는 여러 가지 강력한 촉진요인에 의해 견인되고 있습니다. 주요 성장 요인은 세계 유전 질환 및 희귀질환의 유병률 증가와 기존의 불치한 질병에 대한 효과적인 치료법의 긴급 미충족 요구가 결합되어 혁신적인 AAV 기반 치료 솔루션에 대한 큰 시장 수요를 창출하고 있다는 것입니다.
벡터 엔지니어링에서 중요한 기술적 진보, 특히 조직 특이성을 강화하고 트랜스덕션 효율을 향상시킨 새로운 AAV 캡시드의 개발은 이러한 치료법의 치료 가능성과 임상 응용 범위를 극적으로 확대했습니다. 미국 FDA와 유럽 의약품청(EMA) 등의 규제기관이 확립한 지원적인 규제 프레임워크, 특히 희소질환 치료제의 신속 승인 프로세스와 오펀드래그 지정 제도는 AAV 유전자 치료의 개발 스케줄과 시장 진입을 가속화하고 있습니다.
그러나 시장에는 현저한 제약이 존재합니다. 그 주요 요인은 AAV 벡터 생산에 수반되는 매우 높은 제조 비용이며, 이는 치료비의 상승으로 이어져 환자의 접근을 제한함과 동시에 세계의 헬스케어 제도에 있어서 상환상의 과제를 만들어내고 있습니다.
또한 AAV 벡터에 대한 면역원성 반응과 유전독성 위험과 같은 잠재적인 안전 문제는 여전히 제품 승인 및 시장 침투를 지연시킬 수 있는 규제 장벽으로 여전히 존재합니다. 이러한 과제가 있음에도 불구하고 시장에는 큰 기회가 있습니다. 이는 희소유전성 질환을 넘어 심혈관질환, 신경 퇴행성 질환, 안과질환 등 보다 일반적인 질환에 대한 치료 응용이 확대되고 있는 것 외에도 부유세포 배양 시스템이나 신규 정제법 등 신흥 제조 기술이 생산 비용 절감과 확장성 향상을 약속하며, 결국 시장의 접근성과 성장 가능성을 높일 것으로 기대됩니다.
이 보고서의 주요 특징
- 본 보고서는 세계의 AAV 유전자 치료 시장을 상세하게 분석하여 2024년을 기준 연도로 한 예측기간(2025-2032년) 시장 규모 및 CAGR을 제공합니다.
- 또한 각 부문의 잠재적인 수익 기회를 밝히고 이 시장의 매력적인 투자 제안 행렬을 설명합니다.
- 또한 시장 성장 촉진요인 및 억제요인과 기회, 신제품의 상시와 승인, 시장 동향, 지역별 전망, 주요기업이 채택하는 경쟁 전략 등에 관한 중요한 고찰도 제공합니다.
- 세계 AAV 유전자 치료 시장의 주요 기업 프로파일은 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등 다음 매개변수를 기반으로 게재됩니다.
- 이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형 업데이트, 시장 확대, 마케팅 전술에 대한 충분한 정보를 바탕으로 의사 결정을 내릴 수 있습니다.
- '세계 AAV 유전자 치료 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해관계자를 지원합니다.
- 이해관계자는 세계의 AAV 유전자 치료 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사 결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 전제조건
- 분석 목적
- 전제조건
- 약어
제2장 시장 전망
- 보고서 설명
- 시장 정의와 범위
- 주요 요약
제3장 시장 역학, 규제 및 동향 분석
- 시장 역학
- 성장 촉진요인
- 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 시나리오
- 제품 출시/승인
- PEST 분석
- Porter's Five Forces 분석
- 기업 합병 및 인수(M&A) 시나리오
- 업계 동향
제4장 세계의 AAV 유전자 치료 시장 : 벡터 혈청형별(2020-2032년)
- AAV9
- AAV2
- AAV5
- AAV8
- AAV1
- 엔지니어드/합성 AAV 변이체
제5장 세계의 AAV 유전자 치료 시장 : 치료 영역별(2020-2032년)
- 신경계 질환
- 안과 질환
- 희귀 유전 질환
- 혈액 질환
- 근육 질환
- 대사 질환
- 심혈관 질환
- 종양
- 기타
제6장 세계 AAV 유전자 치료 시장 : 표적 조직별(2020-2032년)
- 중추신경계
- 눈/망막
- 간
- 근육
- 폐
- 심장
- 혈액 및 골수
제7장 세계의 AAV 유전자 치료 시장 : 투여 경로별(2020-2032년)
- 정맥내 투여
- 척수강 내
- 뇌내 투여
- 망막하
- 유리체내 투여
- 근육내
- 심장내 투여
제8장 세계 AAV 유전자 치료 시장 : 적응증유형별(2020-2032년)
- 단일 유전자 질환
- 다인자 질환
제9장 세계의 AAV 유전자 치료 시장 : 유전자 탑재 기준별(2020-2032년)
- 유전자 교체
- 유전자 억제
- 유전자 보강
제10장 세계의 AAV 유전자 치료 시장 : 개발 단계별(2020-2032년)
- 전임상 단계
- 제I상
- 제II상
- 제III상
제11장 세계의 AAV 유전자 치료 시장 : 제조유형별(2020-2032년)
- 자사 제조
- 수탁 제조(CDMO/CMO)
제12장 세계의 AAV 유전자 치료 시장 : 최종 사용자별(2020-2032년)
- 바이오 의약품 기업
- 연구기관 및 학술센터
- 병원 및 전문 클리닉
- 기타(CRO)
제13장 세계의 AAV 유전자 치료 시장 : 지역별(2020-2032년)
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC
- 이스라엘
- 기타 중동
- 아프리카
- 남아프리카
- 북아프리카
- 중앙 아프리카
제14장 경쟁 구도
- Novartis(AveXis)
- Spark Therapeutics(Roche)
- BioMarin Pharmaceutical
- Sarepta Therapeutics
- uniQure
- Regenxbio
- Audentes Therapeutics(Astellas)
- Voyager Therapeutics
- MeiraGTx
- Asklepios BioPharmaceutical(AskBio-Bayer)
- Krystal Biotech
- Genethon
- BridgeBio Gene Therapy
- Passage Bio
- Solid Biosciences
제15장 애널리스트의 제안
- 기회
- 애널리스트의 견해
- Coherent Opportunity Map(COM)
제16장 참고문헌과 분석 방법
- 참고문헌
- 분석 방법
- Coherent Market Insights에 대해
AAV Gene Therapy Market is estimated to be valued at USD 3.46 Bn in 2025 and is expected to reach USD 16.97 Bn by 2032, growing at a compound annual growth rate (CAGR) of 25.5% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 3.46 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 25.50% | 2032 Value Projection: | USD 16.97 Bn |
The global AAV gene therapy market represents a revolutionary frontier in modern medicine, utilizing Adeno-Associated Virus (AAV) vectors as sophisticated delivery systems to transport therapeutic genes directly into target cells for treating various genetic disorders and acquired diseases.
AAV gene therapy has emerged as a groundbreaking therapeutic approach due to its exceptional safety profile, minimal immunogenicity, and ability to achieve long-lasting gene expression without integrating into the host genome.
This innovative treatment modality leverages the unique characteristics of AAV vectors, which are naturally occurring, non-pathogenic viruses that have been extensively engineered to remove their replicative capacity while retaining their remarkable ability to transduce both dividing and non-dividing cells across multiple tissue types.
The market encompasses a diverse range of therapeutic applications including inherited retinal diseases, hemophilia, spinal muscular atrophy, and various central nervous system disorders, with numerous clinical trials demonstrating promising efficacy outcomes. As regulatory agencies worldwide continue to approve AAV-based gene therapies and pharmaceutical companies intensify their research and development efforts, the market is experiencing unprecedented growth driven by technological advancements in vector engineering, improved manufacturing processes, and expanding therapeutic targets that collectively position AAV gene therapy as a transformative solution for previously untreatable genetic conditions.
Market Dynamics
The global AAV gene therapy market is propelled by several compelling drivers that collectively fuel its robust expansion across the healthcare landscape. The primary growth catalyst stems from the increasing prevalence of genetic disorders and rare diseases worldwide, coupled with the urgent unmet medical need for effective treatments in conditions previously deemed incurable, creating substantial market demand for innovative AAV-based therapeutic solutions.
Significant technological advancements in vector engineering, including the development of novel AAV capsids with enhanced tissue specificity and improved transduction efficiency, have dramatically expanded the therapeutic potential and clinical applicability of these treatments. Supportive regulatory frameworks established by agencies such as the U.S. FDA and EMA, including expedited approval pathways for rare disease treatments and orphan drug designations, have accelerated the development timeline and market entry for AAV gene therapies.
However, the market faces notable restraints primarily centered around the exceptionally high manufacturing costs associated with AAV vector production, which translates into substantial treatment expenses that limit patient accessibility and create reimbursement challenges for healthcare systems globally.
Additionally, potential safety concerns including immunogenic responses to AAV vectors and the risk of genotoxicity continue to pose regulatory hurdles that may delay product approvals and market penetration. Despite these challenges, the market presents tremendous opportunities driven by expanding therapeutic applications beyond rare genetic diseases into more prevalent conditions such as cardiovascular diseases, neurodegenerative disorders, and ophthalmologic conditions, while emerging manufacturing technologies including suspension cell culture systems and novel purification methods promise to reduce production costs and improve scalability, ultimately enhancing market accessibility and growth potential.
Key Features of the Study
- This report provides in-depth analysis of the global AAV gene therapy market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global AAV gene therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Novartis (AveXis), Spark Therapeutics (Roche), BioMarin Pharmaceutical, Sarepta Therapeutics, uniQure, Regenxbio, Audentes Therapeutics (Astellas), Voyager Therapeutics, MeiraGTx, Asklepios BioPharmaceutical (AskBio - Bayer), Krystal Biotech, Genethon, BridgeBio Gene Therapy, Passage Bio, and Solid Biosciences
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global AAV gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global AAV gene therapy market
Market Segmentation
- Vector Serotype Insights (Revenue, USD Bn, 2020 - 2032)
- AAV9
- AAV2
- AAV5
- AAV8
- AAV1
- Engineered/Synthetic AAV Variants
- Therapeutic Area Insights (Revenue, USD Bn, 2020 - 2032)
- Neurological Disorders
- Ophthalmic Disorders
- Rare Genetic Disorders
- Hematological Disorders
- Muscular Disorders
- Metabolic Disorders
- Cardiovascular Disorders
- Oncology
- Others
- Target Tissue Insights (Revenue, USD Bn, 2020 - 2032)
- Central Nervous System
- Eye/Retina
- Liver
- Muscle
- Lung
- Heart
- Blood/Bone Marrow
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Intravenous
- Intrathecal
- Intracerebral
- Subretinal
- Intravitreal
- Intramuscular
- Intracardiac
- Indication Type Insights (Revenue, USD Bn, 2020 - 2032)
- Monogenic Disorders
- Polygenic Disorders
- Gene Payload Type Insights (Revenue, USD Bn, 2020 - 2032)
- Gene Replacement
- Gene Silencing
- Gene Augmentation
- Development Stage Insights (Revenue, USD Bn, 2020 - 2032)
- Preclinical
- Phase I
- Phase II
- Phase III
- Manufacturing Type Insights (Revenue, USD Bn, 2020 - 2032)
- In-house Manufacturing
- Contract Manufacturing (CDMO/CMO)
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Biopharmaceutical Companies
- Research Institutes and Academic Centers
- Hospitals and Specialty Clinics
- Others (CROs)
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Novartis (AveXis)
- Spark Therapeutics (Roche)
- BioMarin Pharmaceutical
- Sarepta Therapeutics
- uniQure
- Regenxbio
- Audentes Therapeutics (Astellas)
- Voyager Therapeutics
- MeiraGTx
- Asklepios BioPharmaceutical (AskBio - Bayer)
- Krystal Biotech
- Genethon
- BridgeBio Gene Therapy
- Passage Bio
- Solid Biosciences
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global AAV Gene Therapy Market, By Vector Serotype
- Global AAV Gene Therapy Market, By Therapeutic Area
- Global AAV Gene Therapy Market, By Target Tissue
- Global AAV Gene Therapy Market, By Route of Administration
- Global AAV Gene Therapy Market, By Indication Type
- Global AAV Gene Therapy Market, By Gene Payload Type
- Global AAV Gene Therapy Market, By Development Stage
- Global AAV Gene Therapy Market, By Manufacturing Type
- Global AAV Gene Therapy Market, By End User
- Global AAV Gene Therapy Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global AAV Gene Therapy Market, By Vector Serotype, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- AAV9
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- AAV2
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- AAV5
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- AAV8
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- AAV1
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Engineered/Synthetic AAV Variants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global AAV Gene Therapy Market, By Therapeutic Area, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Neurological Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ophthalmic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Rare Genetic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hematological Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Muscular Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Metabolic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Cardiovascular Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global AAV Gene Therapy Market, By Target Tissue, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Central Nervous System
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Eye/Retina
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Liver
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Muscle
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Lung
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Heart
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Blood/Bone Marrow
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global AAV Gene Therapy Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intrathecal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intracerebral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Subretinal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intravitreal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intramuscular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intracardiac
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global AAV Gene Therapy Market, By Indication Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Monogenic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Polygenic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global AAV Gene Therapy Market, By Gene Payload Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Gene Replacement
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Gene Silencing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Gene Augmentation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global AAV Gene Therapy Market, By Development Stage, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Preclinical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Phase I
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Phase II
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Phase III
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global AAV Gene Therapy Market, By Manufacturing Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- In-house Manufacturing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Contract Manufacturing (CDMO/CMO)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
12. Global AAV Gene Therapy Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Biopharmaceutical Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Research Institutes and Academic Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hospitals and Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others (CROs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
13. Global AAV Gene Therapy Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Vector Serotype, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Tissue, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gene Payload Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Development Stage, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Vector Serotype, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Tissue, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gene Payload Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Development Stage, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Vector Serotype, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Tissue, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gene Payload Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Development Stage, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Vector Serotype, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Tissue, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gene Payload Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Development Stage, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Vector Serotype, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Tissue, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gene Payload Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Development Stage, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Vector Serotype, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Tissue, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gene Payload Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Development Stage, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
14. Competitive Landscape
- Novartis (AveXis)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Spark Therapeutics (Roche)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BioMarin Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sarepta Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- uniQure
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Regenxbio
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Audentes Therapeutics (Astellas)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Voyager Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- MeiraGTx
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Asklepios BioPharmaceutical (AskBio - Bayer)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Krystal Biotech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Genethon
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BridgeBio Gene Therapy
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Passage Bio
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Solid Biosciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
15. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
16. References and Research Methodology
- References
- Research Methodology
- About us
